Erica ( Yun-Chen) T.

• Development of current and new protocols on a variety of sample types such as whole blood, FFPE tissue samples and plasma. (e.g. bulk RNA-Seq, Drug-Seq, scRNA-Seq, Smart-Seq, Total-Seq, CITE-Seq, and long-reads sequencing Nanopore sequencing platform). • Tested and validated a low-cost and HTS NGS based (3’UPX kit) to proof-of-concept screening for novel compound mechanistic studies and compound repurposing efforts. • Designed and developed PCR-based assays for quantifying gene expression. • Conceptualized, developed, and executed evaluations of platforms, vendors, and emerging technologies of clinical and translational utility and applied this knowledge to address Skyhawk needs. • Planned and executed projects successfully to meet tight timelines which involved coordinating internal and external team members. • Provided scientific and operational oversight of CROs and other ancillary vendors. • Maintained sample tracking, electrical lab notebooks, compiled data, and inventory necessary to execute NGS cycles.

• Developed, validated and troubleshoot of Single Cell assays including Single Cell RNA sequencing, Smart Seq and CITI-Seq on difficult clinical specimen. • Optimized of tissues dissociation, stabilized, immune cell purification and PBMC isolation protocols. • Hand on 10X Genomic Single Cell 3’ and 5’ whole transcriptome profiling and VDJ sequencing. • Applied RNA-Seq, Single Cell RNA Seq and ChIP Seq to characterize how epigenetic factors regulated tumors. • Increased efficiency of exciting workflows through optimized and automation. • Established functional assay used various techniques including imaging, ELSA, and FACS. • Collaboratively worked with several cores such as bioinformatics, sequencing and flow cytometer core. • Lead contributor to the design and development of new tissue dissociation and flow cytometry sorting protocols, implemented into pipelines for profiling human, mouse, rat, and monkey for 10X Genomic Single Cell Sequencing and Smart Sequencing platforms. • Led research projects in cancer biomarkers and drug discovery at BUMC, BU, Pharma and Bio-tech collaborations using Single Cell Sequencing technologies. • Offer intensive project support to over 100 academic and industrial clients.

• Developed and improved protocols for human iPSC/ESC to cardiomyocyte, hepatocytes and neuron cells. • Reprogrammed human skin fibroblasts and hematopoietic stem cell by retroviral methods into iPSC stem cells. • Gene expression profiling experimental design, RNA isolation and QC, differential gene expression analysis follow up validation with QPCR and providing biomarkers and MOA based on expression and pathway analysis. • Optimized transfection conditions for of genome-editing tools such as CRISPR and siRNA overexpression construct delivery. • Development of multiplexed phenotypic assays for cellular and drug target biology utilizing chemical genomics, RNAi, lentivirus, CRISPR, and overexpression platforms. • Next generation RNA sequencing samples QC, library preparation, and data analysis.

• Differentiation of human Cardiac iPSCs for Drug Screening & Discovery. • Phenotypic Screens in 96-well format to identify and validate targets for CVD using physiologically relevant cell models (differentiated cell lines, stem cells, primary cells) • Next generation RNA sequencing samples QC, library preparation, data analysis. • Developed animal models to predict variation of drugs response and Drug-Drug interaction. • Collaborated with PI and colleague to conceptualize, edit, and contribute data to an NIH R01 grant.

• Dose-response expression profiling for MOA study of compound efficacy, toxicity, and off-target activity in tissue culture. • Compound profiling and mechanism of actions studies for therapeutic molecules against a broad range of molecular targets, including enzymes kinetics and GPCRs. • Established international collaboration with leading lab to test "actives" from a screen of 10K compounds, and identified compounds for further testing in preclinical trials. • Phase II study of PHY906 combining CPT-11 in advanced hepatocellular carcinoma. • Collaborated with PI and colleague to conceptualize, edit, and contribute data to an NIH R01 grant.

• Developed and executing relevant cardiovascular disease, in vitro and in vivo experiments to evaluate the efficacy and mode of action of novel drug candidates. • Assisted principal investigator in grant-writing to secure funding of $20K from China Medical University for research to identify two nature products to treatment with cardiovascular diseases. • Discovery of novel therapeutic targets for cardiac gene therapy. • Discovery of autophagy regulators for treatment of neurodegenerative diseases.

★ Designed and set up in vitro high throughput screening for neuron regeneration compounds. ★ Studies the molecular mechanisms leading to normal brain aging and the pathological processes that culminate in Alzheimer’s disease and multiple sclerosis.

★Explored cellular and molecular mechanisms behind obesity-accelerated cardiovascular disease in diabetic rats. ★ Established and managed a cross-institutional collaboration with a biopharmaceutical industry leader in Taiwan.